Complement activation by (auto-) antibodies

Molecular Immunology

Volumn 48, Issue 14, 2011, Pages 1656-1665

  Daha, Nina A ^a   Banda, Nirmal K ^b   Roos, Anja ^a   Beurskens, Frank J ^c   Bakker, Joost M ^c   Daha, Mohamed R ^a   Trouw, Leendert A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c GENMAB   (Netherlands)

Author keywords

Antibody; Autoimmunity; Complement; Therapy

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; AUTOANTIBODY; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT FACTOR H; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RITUXIMAB;

ARTHRITIS; COMPLEMENT ACTIVATION; COMPLEMENT LECTIN PATHWAY; CYTOLYSIS; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; COMPLEMENT ACTIVATION; DISEASE MODELS, ANIMAL; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; PEMPHIGOID, BULLOUS;

EID: 79960460140     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2011.04.024     Document Type: Review

References (156)

1. Arnold J.N., Wormald M.R., Suter D.M., Radcliffe C.M., Harvey D.J., Dwek R.A., Rudd P.M., Sim R.B. Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J. Biol. Chem. 2005, 280:29080-29087.
2. Atkinson J.P., Oglesby T.J., White D., Adams E.A., Liszewski M.K. Separation of self from non-self in the complement system: a role for membrane cofactor protein and decay accelerating factor. Clin. Exp. Immunol. 1991, 86(Suppl. 1):27-30.
3. Backlund J., Carlsen S., Hoger T., Holm B., Fugger L., Kihlberg J., Burkhardt H., Holmdahl R. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc. Natl. Acad. Sci. U.S.A. 2002, 9960-9965.
4. Banda N.K., Levitt B., Wood A.K., Takahashi K., Stahl G.L., Holers V.M., Arend W.P. Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro. Clin. Exp. Immunol. 2010, 100-108.
5. Banda N.K., Takahashi K., Wood A.K., Holers V.M., Arend W.P. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J. Immunol. 2007, 4101-4109.
6. Banda N.K., Takahashi M., Levitt B., Glogowska M., Nicholas J., Takahashi K., Stahl G.L., Fujita T., Arend W.P., Holers V.M. Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis. J. Immunol. 2010, 5598-5606.
7. Banda N.K., Thurman J.M., Kraus D., Wood A., Carroll M.C., Arend W.P., Holers V.M. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J. Immunol. 2006, 1904-1912.
8. Banda N.K., Wood A.K., Takahashi K., Levitt B., Rudd P.M., Royle L., Abrahams J.L., Stahl G.L., Holers V.M., Arend W.P. Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. Arthritis Rheum. 2008, 3081-3089.
9. Beum P.V., Lindorfer M.A., Beurskens F., Stukenberg P.T., Lokhorst H.M., Pawluczkowycz A.W., Parren P.W., van de Winkel J.G., Taylor R.P. Complement activation on B lymphocytes opsonized with rituximab or of atumumab produces substantial changes in membrane structure preceding cell lysis. J. Immunol. 2008, 181:822-832.
10. Biesecker G., Katz S., Koffler D. Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis. J. Exp. Med. 1981, 1779-1794.
11. Bigler C., Hopfer H., Danner D., Schaller M., Mihatsch M.J., Trendelenburg M. Anti-C1q autoantibodies do not correlate with the occurrence or severity of experimental lupus nephritis. Nephrol. Dial. Transplant. 2010.
12. Bindon C.I., Hale G., Bruggemann M., Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J. Exp. Med. 1988, 168:127-142.
13. Blok V.T., Gelderman K.A., Tijsma O.H., Daha M.R., Gorter A. Cytokines affect resistance of human renal tumour cells to complement-mediated injury. Scand. J. Immunol. 2003, 57:591-599.
14. Boross, P., Jansen, J.M.H., de Haij, S., Beurskens, F.J., van der Poel, C.E., Bevaart, L., Nederend, M., Golay, J., van de Winkel, J.G.J., Parren, P.W.H.I., Jeanette, H.W., Leusen, J.W.H., 2011. Tumor burden affects mechanism of action of CD20 monoclonal antibodies. submitted for publication.
15. Burton D.R., Boyd J., Brampton A.D., Easterbrook-Smith S.B., Emanuel E.J., Novotny J., Rademacher T.W., van Schravendijk M.R., Sternberg M.J., Dwek R.A. The Clq receptor site on immunoglobulin G. Nature 1980, 288:338-344.
16. Chen R., Ning G., Zhao M.L., Fleming M.G., Diaz L.A., Werb Z., Liu Z. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J. Clin. Invest. 2001, 1151-1158.
17. Collins C., Tsui F.W., Shulman M.J. Differential activation of human and guinea pig complement by pentameric and hexameric IgM. Eur. J. Immunol. 2002, 32:1802-1810.
18. Couser W.G., Baker P.J., Adler S. Complement and the direct mediation of immune glomerular injury: a new perspective. Kidney Int. 1985, 879-890.
19. Cragg M.S., Morgan S.M., Chan H.T., Morgan B.P., Filatov A.V., Johnson P.W., French R.R., Glennie M.J. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003, 101:1045-1052.
20. Cruz R.I., Hernandez-Ilizaliturri F.J., Olejniczak S., Deeb G., Knight J., Wallace P., Thurberg B.L., Kennedy W., Czuczman M.S. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leuk. Lymphoma 2007, 48:2424-2436.
21. Daha M.R., Deelder A.M., Van Es L.A. Stabilization of the amplification convertase of complement by monoclonal antibodies directed against human factor B. J. Immunol. 1984, 132:2538-2542.
22. Daha M.R., Fearon D.T., Austen K.F. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J. Immunol. 1976, 116:1-7.
23. Daha M.R., Hazevoet H.M., Van Es L.A., Cats A. Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus. Immunology 1980, 40:417-424.
24. Daha M.R., Van Es L.A. Stabilization of homologous and heterologous cell-bound amplification convertases C3bBb, by C3 nephritic factor. Immunology 1981, 43:33-38.
25. Dall'Acqua W.F., Cook K.E., Damschroder M.M., Woods R.M., Wu H. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J. Immunol. 2006, 177:1129-1138.
26. Davis A.C., Roux K.H., Shulman M.J. On the structure of polymeric IgM. Eur. J. Immunol. 1988, 18:1001-1008.
27. de Weers W.M., Tai Y.T., van der Veer M.S., Bakker J.M., Vink T., Jacobs D.C., Oomen L.A., Peipp M., Valerius T., Slootstra J.W., Mutis T., Bleeker W.K., Anderson K.C., Lokhorst H.M., van de Winkel J.G., Parren P.W. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 2011, 186:1840-1848.
28. Di Gaetano G.N., Cittera E., Nota R., Vecchi A., Grieco V., Scanziani E., Botto M., Introna M., Golay J. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 2003, 171:1581-1587.
29. Donaldson V.H., Wagner C.J., Davis A.E. An autoantibody to C1-inhibitor recognizes the reactive center of the inhibitor. J. Lab. Clin. Med. 1996, 127:229-232.
30. Dragon-Durey M.A., Blanc C., Garnier A., Hofer J., Sethi S.K., Zimmerhackl L.B. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Semin. Thromb. Hemost. 2010, 36:633-640.
31. Dragon-Durey M.A., Sethi S.K., Bagga A., Blanc C., Blouin J., Ranchin B., Andre J.L., Takagi N., Cheong H.I., Hari P., Le Q.M., Niaudet P., Loirat C., Fridman W.H., Fremeaux-Bacchi V. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2010, 21:2180-2187.
32. Duncan A.R., Winter G. The binding site for C1q on IgG. Nature 1988, 332:738-740.
33. Elliott M.K., Jarmi T., Ruiz P., Xu Y., Holers V.M., Gilkeson G.S. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int. 2004, 129-138.
34. Endo M., Ohi H., Ohsawa I., Fujita T., Matsushita M. Complement activation through the lectin pathway in patients with Henoch-Schonlein purpura nephritis. Am. J. Kidney Dis. 2000, 35:401-407.
35. Endo M., Ohi H., Ohsawa I., Fujita T., Matsushita M., Fujita T. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol. Dial. Transplant. 1998, 13:1984-1990.
36. Espinosa M., Ortega R., Gomez-Carrasco J.M., Lopez-Rubio F., Lopez-Andreu M., Lopez-Oliva M.O., Aljama P. Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. Nephrol. Dial. Transplant. 2009, 24:886-891.
37. Falk R.J., Dalmasso A.P., Kim Y., Tsai C.H., Scheinman J.I., Gewurz H., Michael A.F. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J. Clin. Invest. 1983, 560-573.
38. Fasching C.E., Grossman T., Corthesy B., Plaut A.G., Weiser J.N., Janoff E.N. Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae. Infect. Immun. 2007, 75:1801-1810.
39. Fearon D.T., Austen K.F. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J. Exp. Med. 1975, 142:856-863.
40. Fries L.F., Gaither T.A., Hammer C.H., Frank M.M. C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J. Exp. Med. 1984, 160:1640-1655.
41. Fuenmayor J., Perez-Vazquez K., Perez-Witzke D., Penichet M.L., Montano R.F. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg. Mol. Cancer Ther. 2010, 9:2175-2185.
42. Fung M., Loubser P.G., Undar A., Mueller M., Sun C., Sun W.N., Vaughn W.K., Fraser C.D. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J. Thorac. Cardiovasc. Surg. 2001, 113-122.
43. Gelderman K.A., Tomlinson S., Ross G.D., Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 2004, 25:158-164.
44. Gigli I., Sorvillo J., Halbwachs-Mecarelli L. Regulation and deregulation of the fluid-phase classical pathway C3 convertase. J. Immunol. 1985, 135:440-444.
45. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 2007, 44:3823-3837.
46. Golay J., Cittera E., Di G.N., Manganini M., Mosca M., Nebuloni M., van R.N., Vago L., Introna M. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006, 91:176-183.
47. Golay J., Zaffaroni L., Vaccari T., Lazzari M., Borleri G.M., Bernasconi S., Tedesco F., Rambaldi A., Introna M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000, 95:3900-3908.
48. Gudi V.S., White M.I., Cruickshank N., Herriot R., Edwards S.L., Nimmo F., Ormerod A.D. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br. J. Dermatol. 2005, 424-427.
49. Hiemstra P.S., Biewenga J., Gorter A., Stuurman M.E., Faber A., Van Es L.A., Daha M.R. Activation of complement by human serum IgA, secretory IgA and IgA1 fragments. Mol. Immunol. 1988, 25:527-533.
50. Hiemstra P.S., Gorter A., Stuurman M.E., Van Es L.A., Daha M.R. Activation of the alternative pathway of complement by human serum IgA. Eur. J. Immunol. 1987, 17:321-326.
51. Hietala M.A., Nandakumar K.S., Persson L., Fahlen S., Holmdahl R., Pekna M. Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis. Eur. J. Immunol. 2004, 1208-1216.
52. Hisano S., Matsushita M., Fujita T., Endo Y., Takebayashi S. Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis. Am. J. Kidney Dis. 2001, 38:1082-1088.
53. Hogarth M.B., Norsworthy P.J., Allen P.J., Trinder P.K., Loos M., Morley B.J., Walport M.J., Davies K.A. Autoantibodies to the collagenous region of C1q occur in three strains of lupus-prone mice. Clin. Exp. Immunol. 1996, 104:241-246.
54. Hourcade D.E. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J. Biol. Chem. 2006, 2128-2132.
55. Hughes-Jones N.C., Gardner B. The reaction between the complement subcomponent C1q, IgG complexes and polyionic molecules. Immunology 1978, 34:459-463.
56. Idusogie E.E., Presta L.G., Gazzano-Santoro H., Totpal K., Wong P.Y., Ultsch M., Meng Y.G., Mulkerrin M.G. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 2000, 164:4178-4184.
57. Idusogie E.E., Wong P.Y., Presta L.G., Gazzano-Santoro H., Totpal K., Ultsch M., Mulkerrin M.G. Engineered antibodies with increased activity to recruit complement. J. Immunol. 2001, 166:2571-2575.
58. Janoff E.N., Fasching C., Orenstein J.M., Rubins J.B., Opstad N.L., Dalmasso A.P. Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. J. Clin. Invest. 1999, 104:1139-1147.
59. Jelezarova E., Lutz H.U. Assembly and regulation of the complement amplification loop in blood: the role of C3b-C3b-IgG complexes. Mol. Immunol. 1999, 36:837-842.
60. Jelezarova E., Vogt A., Lutz H.U. Interaction of C3b(2)-IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification. Biochem. J. 2000, 349:217-223.
61. Ji H., Ohmura K., Mahmood U., Lee D.M., Hofhuis F.M., Boackle S.A., Takahashi K., Holers V.M., Walport M., Gerard C., Ezekowitz A., Carroll M.C., Brenner M., Weissleder R., Verbeek J.S., Duchatelle V., Degott C., Benoist C., Mathis D. Arthritis critically dependent on innate immune system players. Immunity 2002, 157-168.
62. 2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J. Immunol. 2000, 164:6075-6081.
63. Kalli K.R., Hsu P., Fearon D.T. Therapeutic uses of recombinant complement protein inhibitors. Springer Semin. Immunopathol. 1994, 417-431.
64. Kennedy A.D., Beum P.V., Solga M.D., DiLillo D.J., Lindorfer M.A., Hess C.E., Densmore J.J., Williams M.E., Taylor R.P. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 2004, 172:3280-3288.
65. Kim D.D., Song W.C. Membrane complement regulatory proteins. Clin. Immunol. 2006, 118:127-136.
66. Kimura Y., Zhou L., Miwa T., Song W.C. Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury. J. Clin. Invest. 2010, 3545-3554.
67. Kirkitadze M.D., Dryden D.T., Kelly S.M., Price N.C., Wang X., Krych M., Atkinson J.P., Barlow P.N. Co-operativity between modules within a C3b-binding site of complement receptor type 1. FEBS Lett. 1999, 459:133-138.
68. Klepfish A., Rachmilewitz E.A., Kotsianidis I., Patchenko P., Schattner A. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. QJM 2008, 101:737-740.
69. Kuhn K.A., Kulik L., Tomooka B., Braschler K.J., Arend W.P., Robinson W.H., Holers V.M. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J. Clin. Invest. 2006, 961-973.
70. Langan S.M., Smeeth L., Hubbard R., Fleming K.M., Smith C.J., West J. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ 2008, a180.
71. Lapiere J.C., Woodley D.T., Parente M.G., Iwasaki T., Wynn K.C., Christiano A.M., Uitto J. Epitope mapping of type VII collagen Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J. Clin. Invest. 1993, 1831-1839.
72. Li Q., Ujiie H., Shibaki A., Wang G., Moriuchi R., Qiao H.J., Morioka H., Shinkuma S., Natsuga K., Long H.A., Nishie W., Shimizu H. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model. J. Immunol. 2010, 7746-7755.
73. Liszewski M.K., Atkinson J.P. Membrane cofactor protein (MCP; CD46). Isoforms differ in protection against the classical pathway of complement. J. Immunol. 1996, 156:4415-4421.
74. Liu Z., Sui W., Zhao M., Li Z., Li N., Thresher R., Giudice G.J., Fairley J.A., Sitaru C., Zillikens D., Ning G., Marinkovich M.P., Diaz L.A. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J. Autoimmun. 2008, 331-338.
75. Mackworth-Young C.G., Chan J.K., Bunn C.C., Hughes G.R., Gharavi A.E. Complement fixation by anti-dsDNA antibodies in SLE: measurement by radioimmunoassay and relationship with disease activity. Ann. Rheum. Dis. 1986, 314-318.
76. Malhotra R., Wormald M.R., Rudd P.M., Fischer P.B., Dwek R.A., Sim R.B. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1995, 1:237-243.
77. Manches O., Lui G., Chaperot L., Gressin R., Molens J.P., Jacob M.C., Sotto J.J., Leroux D., Bensa J.C., Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101:949-954.
78. Mandik-Nayak L., Allen P.M. Initiation of an autoimmune response: insights from a transgenic model of rheumatoid arthritis. Immunol. Res. 2005, 5-13.
79. Matsuda M., Shikata K., Wada J., Sugimoto H., Shikata Y., Kawasaki T., Makino H. Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. Nephron 1998, 80:408-413.
80. Matsumoto I., Staub A., Benoist C., Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999, 1732-1735.
81. Meszaros T., Fust G., Farkas H., Jakab L., Temesszentandrasi G., Nagy G., Kiss E., Gergely P., Zeher M., Griger Z., Czirjak L., Hobor R., Haris A., Polner K., Varga L. C1-inhibitor autoantibodies in SLE. Lupus 2010, 19:634-638.
82. Michaelsen T.E., Aase A., Westby C., Sandlie I. Enhancement of complement activation and cytolysis of human IgG3 by deletion of hinge exons. Scand. J. Immunol. 1990, 32:517-528.
83. Michaelsen T.E., Sandlie I., Bratlie D.B., Sandin R.H., Ihle O. Structural difference in the complement activation site of human IgG1 and IgG3. Scand. J. Immunol. 2009, 70:553-564.
84. Mihai S., Chiriac M.T., Takahashi K., Thurman J.M., Holers V.M., Zillikens D., Botto M., Sitaru C. The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. J. Immunol. 2007, 6514-6521.
85. Miletic V.D., Frank M.M. Complement-immunoglobulin interactions. Curr. Opin. Immunol. 1995, 7:41-47.
86. Mone A.P., Cheney C., Banks A.L., Tridandapani S., Mehter N., Guster S., Lin T., Eisenbeis C.F., Young D.C., Byrd J.C. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006, 20:272-279.
87. Monk P.N., Pease J.E., Barker M.D. C5a stimulus-secretion coupling in rat basophilic leukaemia (RBL-2H3) cells transfected with the human C5a receptor is mediated by pertussis and cholera toxin-sensitive G proteins. Biochem. Mol. Biol. Int. 1994, 32:13-20.
88. Monova D., Monov S., Rosenova K., Argirova T. Autoantibodies against C1q: view on association between systemic lupus erythematosus disease manifestation and C1q autoantibodies. Ann. Rheum. Dis. 2002, 61:563-564.
89. Moore F.D. Therapeutic regulation of the complement system in acute injury states. Adv. Immunol.. 1994, 267-299.
90. Moore G.L., Chen H., Karki S., Lazar G.A. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2010, 2.
91. Morgan B.P., Rushmere N.K., Harris C.L. Therapeutic uses of recombinant complement receptors. Biochem. Soc. Trans. 1998, 26:49-54.
92. Nandakumar K.S., Collin M., Olsen A., Nimmerjahn F., Blom A.M., Ravetch J.V., Holmdahl R. Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. Eur. J. Immunol. 2007, 2973-2982.
93. Natsume A., Shimizu-Yokoyama Y., Satoh M., Shitara K., Niwa R. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity. Cancer Sci. 2009, 100:2411-2418.
94. Nishie W., Sawamura D., Goto M., Ito K., Shibaki A., McMillan J.R., Sakai K., Nakamura H., Olasz E., Yancey K.B., Akiyama M., Shimizu H. Humanization of autoantigen. Nat. Med. 2007, 378-383.
95. Norsworthy P., Davies K.A. Complement components and their autoantibodies. Mol. Biotechnol. 2003, 23:259-270.
96. Oikarinen A.I., Zone J.J., Ahmed A.R., Kiistala U., Uitto J. Demonstration of collagenase and elastase activities in the blister fluids from bullous skin diseases. Comparison between dermatitis herpetiformis and bullous pemphigoid. J. Invest. Dermatol. 1983, 261-266.
97. Olszewski A.J., Grossbard M.L. Empowering targeted therapy: lessons from rituximab. Sci. STKE 2004, 2004:e30.
98. Oortwijn B.D., Roos A., Royle L., van Gijlswijk-Janssen D.J., Faber-Krol M.C., Eijgenraam J.W., Dwek R.A., Daha M.R., Rudd P.M., van K.C. Differential glycosylation of polymeric and monomeric IgA: a possible role in glomerular inflammation in IgA nephropathy. J. Am. Soc. Nephrol. 2006, 17:3529-3539.
99. Papista C., Berthelot L., Monteiro R.C. Dysfunctions of the IgA system: a common link between intestinal and renal diseases. Cell. Mol. Immunol. 2011, 8:126-134.
100. Papp K., Vegh P., Tchorbanov A., Vassilev T., Erdei A., Prechl J. Progression of lupus-like disease drives the appearance of complement-activating IgG antibodies in MRL/lpr mice. Rheumatology (Oxford) 2010, 2273-2280.
101. Pascual M., Catana E., White T., Spiegelman B.M., Schifferli J.A. Inhibition of complement alternative pathway in mice with Fab antibody to recombinant adipsin/factor D. Eur. J. Immunol. 1993, 1389-1392.
102. Pawluczkowycz A.W., Beurskens F.J., Beum P.V., Lindorfer M.A., van de Winkel J.G., Parren P.W., Taylor R.P. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 2009, 183:749-758.
103. Perianayagam M.C., Balakrishnan V.S., King A.J., Pereira B.J., Jaber B.L. C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway. Kidney Int. 2002, 61:456-463.
104. Polyak M.J., Tailor S.H., Deans J.P. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J. Immunol. 1998, 161:3242-3248.
105. Racila E., Link B.K., Weng W.K., Witzig T.E., Ansell S., Maurer M.J., Huang J., Dahle C., Halwani A., Levy R., Weiner G.J. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin. Cancer Res. 2008, 14:6697-6703.
106. Rantapaa-Dahlqvist S., de Jong B.A., Berglin E., Hallmans G., Wadell G., Stenlund H., Sundin U., van Venrooij W.J. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 2741-2749.
107. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., Anderson D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
108. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
109. Robson M.G., Cook H.T., Pusey C.D., Walport M.J., Davies K.A. Antibody-mediated glomerulonephritis in mice: the role of endotoxin, complement and genetic background. Clin. Exp. Immunol. 2003, 326-333.
110. Roos A., Bouwman L.H., van Gijlswijk-Janssen D.J., Faber-Krol M.C., Stahl G.L., Daha M.R. Human IgA activates the complement system via the mannan-binding lectin pathway. J. Immunol. 2001, 167:2861-2868.
111. Roos A., Rastaldi M.P., Calvaresi N., Oortwijn B.D., Schlagwein N., van Gijlswijk-Janssen D.J., Stahl G.L., Matsushita M., Fujita T., van K.C., Daha M.R. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J. Am. Soc. Nephrol. 2006, 17:1724-1734.
112. Rothfield N.F., Stollar B.D. The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J. Clin. Invest. 1967, 1785-1794.
113. Royle L., Roos A., Harvey D.J., Wormald M.R., van Gijlswijk-Janssen D., Redwan e., Wilson I.A., Daha M.R., Dwek R.A., Rudd P.M. Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J. Biol. Chem. 2003, 278:20140-20153.
114. Schuerwegh A.J., Ioan-Facsinay A., Dorjee A.L., Roos J., Bajema I.M., van der Voort E.I., Huizinga T.W., Toes R.E. Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2586-2591.
115. Seelen M.A., Trouw L.A., Daha M.R. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr. Opin. Nephrol. Hypertens. 2003, 12:619-624.
116. Seelen M.A., Trouw L.A., van der Hoorn J.W., Fallaux-van den Houten F.C., Huizinga T.W., Daha M.R., Roos A. Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clin. Exp. Immunol. 2003, 134:335-343.
117. Seelen M.A., van der Bijl E.A., Trouw L.A., Zuiverloon T.C., Munoz J.R., Fallaux-van den Houten F.C., Schlagwein N., Daha M.R., Huizinga T.W., Roos A. A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44:111-119.
118. Shushakova N., Skokowa J., Schulman J., Baumann U., Zwirner J., Schmidt R.E., Gessner J.E. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J. Clin. Invest. 2002, 110:1823-1830.
119. Siegert C., Daha M., Westedt M.L., van d.V., Breedveld F. IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus. J. Rheumatol. 1991, 18:230-234.
120. Sitaru C., Chiriac M.T., Mihai S., Buning J., Gebert A., Ishiko A., Zillikens D. Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J. Immunol. 2006, 3461-3468.
121. Skerka C., Jozsi M., Zipfel P.F., Dragon-Durey M.A., Fremeaux-Bacchi V. Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb. Haemost. 2009, 101:227-232.
122. Spitzer D., Mitchell L.M., Atkinson J.P., Hourcade D.E. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J. Immunol. 2007, 179:2600-2608.
123. Stahle-Backdahl M., Inoue M., Guidice G.J., Parks W.C. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J. Clin. Invest. 1994, 2022-2030.
124. Strobel S., Zimmering M., Papp K., Prechl J., Jozsi M. Anti-factor B autoantibody in dense deposit disease. Mol. Immunol. 2010, 47:1476-1483.
125. Takahashi M., Ishida Y., Iwaki D., Kanno K., Suzuki T., Endo Y., Homma Y., Fujita T. Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D. J. Exp. Med. 2010, 29-37.
126. Tanhehco E.J., Kilgore K.S., Liff D.A., Murphy K.L., Fung M.S., Sun W.N., Sun C., Lucchesi B.R. The anti-factor D antibody MAb 166-32, inhibits the alternative pathway of the human complement system. Transplant. Proc. 1999, 2168-2171.
127. 2 domain. J. Exp. Med. 1991, 173:1025-1028.
128. Taylor R. Fresh frozen plasma as a complement source. Lancet Oncol. 2007, 8:370-371.
129. Taylor R.P., Lindorfer M.A. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol. 2008, 20:444-449.
130. Taylor R.P., Lindorfer M.A. Antigenic modulation and rituximab resistance. Semin. Hematol. 2010, 47:124-132.
131. Teeling J.L., French R.R., Cragg M.S., van den Brakel J., Pluyter M., Huang H., Chan C., Parren P.W., Hack C.E., Dechant M., Valerius T., van de Winkel J.G., Glennie M.J. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104:1793-1800.
132. Teeling J.L., Mackus W.J., Wiegman L.J., van den Brakel J.H., Beers S.A., French R.R., van M.T., Ebeling S., Vink T., Slootstra J.W., Parren P.W., Glennie M.J., van de Winkel J.G. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 2006, 177:362-371.
133. Terai I., Kobayashi K., Vaerman J.P., Mafune N. Degalactosylated and/or denatured IgA, but not native IgA in any form, bind to mannose-binding lectin. J. Immunol. 2006, 177:1737-1745.
134. Trendelenburg M., Marfurt J., Gerber I., Tyndall A., Schifferli J.A. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum. 1999, 42:187-188.
135. Trinder P.K., Maeurer M.J., Schorlemmer H.U., Loos M. Autoreactivity to mouse C1q in a murine model of SLE. Rheumatol. Int. 1995, 15:117-120.
136. Trouw L.A., Daha M.R. Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. Expert Opin. Biol. Ther. 2005, 5:243-251.
137. Trouw L.A., Groeneveld T.W., Seelen M.A., Duijs J.M., Bajema I.M., Prins F.A., Kishore U., Salant D.J., Verbeek J.S., van K.C., Daha M.R. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J. Clin. Invest. 2004, 114:679-688.
138. Trouw L.A., Haisma E.M., Levarht E.W., van der Woude D., Ioan-Facsinay A., Daha M.R., Huizinga T.W., Toes R.E. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum. 2009, 60:1923-1931.
139. Trouw L.A., Roos A., Daha M.R. Autoantibodies to complement components. Mol. Immunol. 2001, 38:199-206.
140. Trouw L.A., Seelen M.A., Duijs J.M., Wagner S., Loos M., Bajema I.M., van K.C., Roos A., Daha M.R. Activation of the lectin pathway in murine lupus nephritis. Mol. Immunol. 2005, 42:731-740.
141. Trouw L.A., Seelen M.A., Visseren R., Duijs J.M., Benediktsson H., de H.E., Roos A., van K.C., Daha M.R. Anti-C1q autoantibodies in murine lupus nephritis. Clin. Exp. Immunol. 2004, 135:41-48.
142. Uysal H., Bockermann R., Nandakumar K.S., Sehnert B., Bajtner E., Engstrom A., Serre G., Burkhardt H., Thunnissen M.M., Holmdahl R. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J. Exp. Med. 2009, 449-462.
143. Verpoort K.N., Jol-van der Zijde C.M., Papendrecht-van der Voort E.A., Ioan-Facsinay A., Drijfhout J.W., van Tol M.J., Breedveld F.C., Huizinga T.W., Toes R.E. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum. 2006, 3799-3808.
144. Vossenaar E.R., Zendman A.J., van Venrooij W.J., Pruijn G.J. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003, 1106-1118.
145. Waldmann H., Hale G. CAMPATH: from concept to clinic. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2005, 360:1707-1711.
146. Watanabe H., Garnier G., Circolo A., Wetsel R.A., Ruiz P., Holers V.M., Boackle S.A., Colten H.R., Gilkeson G.S. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J. Immunol. 2000, 786-794.
147. West C.D., McAdams A.J., McConvile J.M., Davis N.C., Holland N.H. Hypocomplementemic and normocomplementemic persistent (chronic) glomerulonephritis; clinical and pathologic characteristics. J. Pediatr. 1965, 67(6):1089-1112. (Generic).
148. Wierda W.G., Kipps T.J., Mayer J., Stilgenbauer S., Williams C.D., Hellmann A., Robak T., Furman R.R., Hillmen P., Trneny M., Dyer M.J., Padmanabhan S., Piotrowska M., Kozak T., Chan G., Davis R., Losic N., Wilms J., Russell C.A., Osterborg A. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2010, 28:1749-1755.
149. Wisnieski J.J., Naff G.B. Serum IgG antibodies to C1q in hypocomplementemic urticarial vasculitis syndrome. Arthritis Rheum. 1989, 32:1119-1127.
150. Woodley D.T., Burgeson R.E., Lunstrum G., Bruckner-Tuderman L., Reese M.J., Briggaman R.A. Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen. J. Clin. Invest. 1988, 683-687.
151. Woodley D.T., Chang C., Saadat P., Ram R., Liu Z., Chen M. Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J. Invest. Dermatol. 2005, 958-964.
152. Woodley D.T., Ram R., Doostan A., Bandyopadhyay P., Huang Y., Remington J., Hou Y., Keene D.R., Liu Z., Chen M. Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J. Invest. Dermatol. 2006, 1323-1330.
153. Wyatt R.J., McAdams A.J., Forristal J., Snyder J., West C.D. Glomerular deposition of complement-control proteins in acute and chronic glomerulonephritis. Kidney Int. 1979, 505-512.
154. Xia M.Q., Hale G., Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol. Immunol. 1993, 30:1089-1096.
155. Yae Y., Inaba S., Sato H., Okochi K., Tokunaga F., Iwanaga S. Isolation and characterization of a thermolabile beta-2 macroglycoprotein ('thermolabile substance' or 'Hakata antigen') detected by precipitating (auto) antibody in sera of patients with systemic lupus erythematosus. Biochim. Biophys. Acta 1991, 1078:369-376.
156. Zent C.S., Secreto C.R., LaPlant B.R., Bone N.D., Call T.G., Shanafelt T.D., Jelinek D.F., Tschumper R.C., Kay N.E. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk. Res. 2008, 32:1849-1856.